A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)
Reference Study ID Number: CN42097 https://forpatients.roche.com/
Memorial University of Newfoundland (MUN) - Faculty of Medicine - St. Clare's Mercy Hospital (SCM)(1.5 mi away)Contact
+35 other location
disease or disorder
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and
radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared
with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple
sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.